About Pyrotinib
An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity.
June, 2022. Based on this phase II study, pyrotinib in combination with capecitabine received its first conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer previously exposed to anthracycline or taxane chemotherapy.
Where to Buy Pyrotinib?
Pyrotinib, marketed as Irene (Chinese Brand name :艾瑞妮). Currently only available for purchase in Mainland China.
You can also consult us: @RxLibra